a delphi consensus on the use of a low-dose multicomponent medication for the prevention and early add-on treatment of influenza-like illness

Background: influenza and influenza-like illness (ili), collectively referred to as flu syndrome (fs) in this consensus, represent a major global health burden. their high incidence, with an estimated 1 billion annual cases globally and 3–5 million severe cases, coupled with relatively limited prophylactic and therapeutic options beyond vaccination, underscores a significant challenge in clinical practice.objectives: this study aimed to establish a formal expert consensus on the definition, management, and potential role of a low-dose multicomponent medication (omeogriphi®) as a broad-spectrum strategy for the prevention and early add-on treatment of fs.methods: a modified delphi consensus process was employed. a scientific committee formulated 15 statements across two domains: 1) the definition and epidemiology of fs, and 2) its management, focusing on omeogriphi®. a panel of 112 italian primary care and private practice physicians with experience in using omeogriphi® rated their agreement on a 5-point likert scale. consensus was predefined as ≥66.6% agreement.results: a high level of consensus was achieved on all 15 statements (79%–99% agreement). the panel reached strong agreement on the clinical definition, epidemiological impact, and complication risks of fs. furthermore, there was robust consensus that omeogriphi® is considered a viable option for both prophylaxis and early treatment of fs, with a favorable safety profile. conclusions: this delphi consensus provides expert-driven, clinically relevant insights into the management of fs and the potential role of a low-dose multicomponent medication. the findings consolidate current clinical experience and establish a foundation for designing future rigorous clinical trials to evaluate the efficacy of this approach objectively.